Macrocyclic Compounds Blocking the PD-1/PD-L1 Immune Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and infectious diseases are limited by the immune evasion mechanisms employed by cancerous cells and pathogens through the PD-1/PD-L1 interaction, leading to T cell exhaustion and reduced immune responses.
Innovation Solution
Development of macrocyclic compounds that inhibit the PD-1/PD-L1 protein interaction, enhancing immune responses and potentially treating various diseases, including cancer and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 interaction is allowed to proceed, then cancer cells and pathogens can evade immune detection and T cell exhaustion is reduced, but immune responses are suppressed and cancer progression occurs
Solution Approach 1:
The patent introduces macrocyclic compounds as intermediary substances that bind to PD-1 and prevent its interaction with PD-L1. These compounds act as mediators that block the harmful interaction between cancer cells and the immune system, thereby restoring immune effectiveness without directly attacking cancer cells themselves.
Solution Approach 2:
The invention extracts the critical interaction interface between PD-1 and PD-L1 by developing compounds that selectively bind to PD-1, removing the harmful interaction capability from the system. This extraction approach isolates the problematic interaction and eliminates it through specific molecular blocking.
2Productivity
If conventional cancer treatments are used, then cancer cells can be targeted, but immune evasion mechanisms reduce treatment effectiveness
Solution Approach 1:
The macrocyclic compounds serve as intermediary agents that restore immune system functionality by blocking PD-1/PD-L1 interaction. This intermediary approach enables the immune system to effectively target cancer cells again, enhancing treatment productivity while restoring immune reliability.
Solution Approach 2:
The patent develops a universal blocking mechanism that can be applied across different cancer types and contexts. The macrocyclic compounds provide multi-functional benefits by simultaneously blocking PD-1/PD-L1 interaction, restoring T cell function, and enhancing overall treatment effectiveness regardless of specific cancer characteristics.
3Reliability
If PD-1/PD-L1 pathway is blocked, then immune responses are enhanced and cancer cells become vulnerable, but new therapeutic agents must be developed
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure and properties of therapeutic compounds to achieve optimal PD-1 binding. By adjusting parameters such as molecular size, binding affinity, and pharmacokinetic properties, the invention creates effective macrocyclic compounds that enhance immune responses while managing development complexity.
Data Source
AI summary
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-1 and are capable of inhibiting the interaction of PD-1 with PD-L1. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.